Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial
Frontiers of Medicine · 2025
DOI: 10.1007/s11684-024-1115-1 ↗Kurz gefasst
Klinische Studie (Phase I) in der Zeitschrift Frontiers of Medicine, 2025. Verfasst von Jing Wei und 6 weiteren Autor:innen. Beteiligte Einrichtung: Jiaxing Andicon Biotech Co., Ltd., Jiaxing, 314006, China. Hauptthemen laut MEDLINE: Antiviral Agents, Endonucleases, Influenza, Human. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 18 Literaturangaben.
Abstract (Originalsprache)
ADC189 is a novel drug of cap-dependent endonuclease inhibitor. In our study, its antiviral efficacy was evaluated in vitro and in vivo, and compared with baloxavir marboxil and oseltamivir. A first-in-human phase I study in healthy volunteers included single ascending dose (SAD) and food effect (FE) parts. In the preclinical study, ADC189 showed potent antiviral activity against various types of influenza viruses, including H1N1, H3N2, influenza B virus, and highly pathogenic avian influenza, comparable to baloxavir marboxil. Additionally, ADC189 exhibited much better antiviral efficacy than oseltamivir in H1N1 infected mice. In the phase I study, ADC189 was rapidly metabolized to ADC189-I07, and its exposure increased proportionally with the dose. The terminal elimination half-life (T1/2) ranged from 76.69 to 98.28 hours. Of note, food had no effect on the concentration, clearance, and exposure of ADC189. It was well tolerated, with few treatment-emergent adverse events (TEAEs) reported and no serious adverse events (SAEs). ADC189 demonstrated excellent antiviral efficacy both in vitro and in vivo. It was safe, well-tolerated, and had favorable pharmacokinetic characteristics in healthy volunteers, supporting its potential for single oral dosing in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiaxing Andicon Biotech Co., Ltd., Jiaxing, 314006, China.
- Key Laboratory of Structure-Based Drug Design & Discovery, Ministry of Education, and School of Traditional Chinese Materia Medica, Shenyang Pharmaceutical University, Shenyang, 110016, China.
- Department of Clinical Pharmacology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, China.
- School of Life Sciences and Health Engineering, Jiangnan University, Wuxi, 214122, China. tangcl@jiangnan.edu.cn.
- Department of Clinical Pharmacology, Affiliated Xiaoshan Hospital, Hangzhou Normal University, Hangzhou, 311202, China. cj21_0503@163.com.
Zitieren
APA
Wei, J., Deng, Y., Zhu, X., Xiao, X., Yang, Y., Tang, C., & Chen, J. (2025). Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial. Frontiers of Medicine. https://doi.org/10.1007/s11684-024-1115-1
Vancouver
Wei J, Deng Y, Zhu X, Xiao X, Yang Y, Tang C, et al. Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial. Frontiers of Medicine. 2025. doi:10.1007/s11684-024-1115-1
BibTeX
@article{Wei2025,
author = {Wei, Jing and Deng, Yaping and Zhu, Xiaoyun and Xiao, Xin and Yang, Yang and Tang, Chunlei and Chen, Jian},
title = {Inhibition of cap-dependent endonuclease in influenza virus with ADC189: a pre-clinical analysis and phase I trial},
journal = {Frontiers of Medicine},
year = {2025},
doi = {10.1007/s11684-024-1115-1}
}
EUVIMED